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Background: Hypertrophic cardiomyopathy (HCM) is a sudden death predisposing disease often caused by sarcomeric gene mutations. Several 
metabolic storage diseases can also mimic the phenotypic expression of HCM. We sought to determine the spectrum and prevalence of sarcomeric 
and metabolic gene mutations in patients with clinically suspected HCM.
Methods: DNA sequence analysis of 9 sarcomeric myofilament genes (MYH7, MYBPC3, TNNT2, TNNI3, TNNC1, TPM1, MYL2, MYL3, ACTC) was 
performed for 317 unrelated patients (64% male, age at genetic testing 35.6±22 years) referred to PGxHealth for FAMILION® HCM genetic testing. 
Analysis of 3 HCM phenocopy genes (GLA, PRKAG2, and LAMP2) was performed for a subset (n=224). Variants were evaluated with respect to 
mutation type, location, predicted effect upon the gene products, prior literature, and more than 400 control individuals representative of major U.S. 
populations.
Results: 44% (139/317) of cases tested positive for 120 distinct mutations (66 novel) in 8 of 9 sarcomeric genes. Multiple sarcomeric mutations 
were detected in 9% of cases; no age difference was observed between single and multiple hit cases. MYBPC3 (55%) and MYH7 (29%) were the two 
most frequently mutated genes among cases with a single mutation. MYBPC3 harbored diverse mutation types, including missense (41%), frameshift 
(23%), and splice mutations (25%), while solely missense mutations were detected in MYH7. No age difference was observed between cases with 
a single mutation in MYBPC3 or MYH7. In addition, 2% (5/224) of cases tested positive for 5 novel phenocopy mutations, including three radical 
LAMP2 mutations in late adolescence, and one mutation each in GLA and PRKAG2.
Conclusion: Among patients referred by cardiologists throughout North America for HCM clinical genetic testing, the yield of sarcomeric/
myofilament-HCM was 44%, consistent with previously reported yields from HCM study cohorts. Notably, this analysis suggests 1 in 45 suspected 
HCM patients may suffer metabolic storage diseases mimicking HCM. An accurate diagnosis is relevant because important differences exist between 
sarcomeric HCM and HCM phenocopies in clinical course, management, and prognosis.
